Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Negative Regulator Molecules

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.

Master Transcription Regulators

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...

TGF - β Signaling Pathway

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Visually Interpretable Histopathology-Based Immune Model Predicts T-effector Biology and Response to Immune checkpoint inhibition in Clear Cell Renal Cell Carcinoma Clinical Trial and Contemporary Real-World Datasets.

bioRxiv : the preprint server for biology·2026

Same author

Non-small Cell Lung Cancer in Metastatic Renal Cell Carcinoma Patients.

Clinical genitourinary cancer·2026

Same author

Pathologic Complete Response After Preoperative Ipilimumab and Nivolumab in an HLRCC Patient with Stage III Renal Cell Carcinoma.

Journal of kidney cancer and VHL·2026

Same author

Alkylating agents activate an SLFN11-dependent vulnerability that confers PARP-1 inhibitor sensitivity in kidney cancer.

Journal of experimental & clinical cancer research : CR·2026

Same author

Lactate-Activated GPR132 Signaling Drives a Tumor Microenvironmental Autocrine Metabolic Loop in Kidney Cancer.

Cancer research·2026

Same author

Metastatic tropism of molecularly defined clear-cell renal cell carcinoma clusters.

The Journal of clinical investigation·2026

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Inducible and Reversible Dominant-negative (DN) Protein Inhibition

Inducible and Reversible Dominant-negative (DN) Protein Inhibition

Published on: January 7, 2019

Structural analysis and functional implications of the negative mTORC1 regulator REDD1.

Silvia Vega-Rubin-de-Celis¹, Zeina Abdallah, Lisa Kinch

¹Department of Developmental Biology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.

|February 20, 2010

Summary

The stress-response protein REDD1 inhibits mTORC1, a key regulator of cell growth implicated in cancer. Structural and functional studies reveal a novel REDD1 domain essential for this inhibition, clarifying its mechanism.

Related Experiment Videos

Last Updated: Jun 16, 2026

Inducible and Reversible Dominant-negative (DN) Protein Inhibition

Inducible and Reversible Dominant-negative (DN) Protein Inhibition

Published on: January 7, 2019

Area of Science:

Molecular Biology
Cellular Biology
Structural Biology

Background:

The stress-response protein REDD1 regulates mTORC1, a critical pathway for cell growth and proliferation implicated in cancer.
REDD1 is induced by hypoxia and inhibits mTORC1, a process dependent on the TSC1/TSC2 complex.
Previous models proposed REDD1 inhibits mTORC1 by sequestering 14-3-3 proteins away from TSC2.

Purpose of the Study:

To elucidate the structural basis of REDD1 function and its mechanism of mTORC1 inhibition.
To identify essential functional segments within REDD1 through structure/function analyses.
To investigate the interaction of REDD1 with regulatory proteins like 14-3-3 and TSC2.

Main Methods:

X-ray crystallography to determine the 3D structure of REDD1 at 2.0 A resolution.
Structure-based docking and functional assays to analyze protein interactions.
Mutagenesis studies and sequence conservation mapping to identify critical functional regions.

Main Results:

A novel domain in REDD1, formed by two interdependent segments, was identified with a unique alpha/beta sandwich fold.
Structure-based analyses suggest REDD1 does not directly bind to 14-3-3 proteins.
A critical interaction hotspot on the REDD1 surface was mapped, essential for mTORC1 inhibition.

Conclusions:

REDD1 possesses a novel structural domain crucial for its function in inhibiting mTORC1.
The mechanism of REDD1-mediated mTORC1 inhibition does not involve direct binding to 14-3-3 proteins.
Identification of a key interaction site provides a target for understanding REDD1's role in cancer and stress response.